 Steven Schuster
Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 3 | 2013 | 120 | 0.800 |
Why?
| | Psychotherapy, Group | 1 | 2019 | 64 | 0.610 |
Why?
| | Exercise Therapy | 1 | 2019 | 406 | 0.470 |
Why?
| | Cancer Survivors | 1 | 2019 | 260 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1572 | 0.420 |
Why?
| | Peptide Hydrolases | 1 | 2013 | 109 | 0.410 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2010 | 11 | 0.360 |
Why?
| | Immunoglobulin M | 1 | 2010 | 268 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1318 | 0.280 |
Why?
| | Quality of Life | 1 | 2019 | 2711 | 0.280 |
Why?
| | Breast Neoplasms | 1 | 2019 | 2116 | 0.270 |
Why?
| | Metabolic Syndrome | 1 | 2006 | 339 | 0.200 |
Why?
| | Dexamethasone | 3 | 2013 | 331 | 0.200 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2006 | 238 | 0.190 |
Why?
| | Carcinoma, Renal Cell | 1 | 2023 | 181 | 0.180 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 352 | 0.160 |
Why?
| | Insulin Resistance | 1 | 2006 | 1164 | 0.140 |
Why?
| | Prognosis | 3 | 2019 | 3793 | 0.130 |
Why?
| | Cyclophosphamide | 2 | 2012 | 232 | 0.120 |
Why?
| | Thalidomide | 1 | 2013 | 30 | 0.110 |
Why?
| | Survival Analysis | 2 | 2013 | 1283 | 0.100 |
Why?
| | Polycythemia Vera | 1 | 2012 | 12 | 0.100 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 593 | 0.100 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2013 | 156 | 0.100 |
Why?
| | Boronic Acids | 1 | 2012 | 37 | 0.100 |
Why?
| | Amyloidosis | 1 | 2012 | 39 | 0.100 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2011 | 19 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 86 | 0.090 |
Why?
| | Pyrazines | 1 | 2012 | 88 | 0.090 |
Why?
| | Multimodal Imaging | 1 | 2011 | 107 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 395 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2010 | 97 | 0.090 |
Why?
| | Clone Cells | 1 | 2010 | 258 | 0.090 |
Why?
| | Positron-Emission Tomography | 1 | 2011 | 285 | 0.090 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 211 | 0.090 |
Why?
| | Bone Diseases | 1 | 2010 | 60 | 0.080 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1435 | 0.080 |
Why?
| | Aged | 4 | 2019 | 22068 | 0.080 |
Why?
| | Bone Marrow | 1 | 2010 | 262 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 738 | 0.080 |
Why?
| | Middle Aged | 5 | 2019 | 31024 | 0.070 |
Why?
| | Treatment Outcome | 4 | 2019 | 10256 | 0.070 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1174 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5365 | 0.070 |
Why?
| | Humans | 11 | 2023 | 129078 | 0.070 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3114 | 0.060 |
Why?
| | Survival Rate | 1 | 2010 | 1886 | 0.060 |
Why?
| | Lymphocyte Transfusion | 1 | 2005 | 20 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 755 | 0.060 |
Why?
| | CD28 Antigens | 1 | 2005 | 48 | 0.060 |
Why?
| | CD8 Antigens | 1 | 2005 | 75 | 0.060 |
Why?
| | Remission Induction | 2 | 2019 | 269 | 0.060 |
Why?
| | Autonomic Nervous System | 1 | 2006 | 75 | 0.060 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2006 | 69 | 0.060 |
Why?
| | Lymphoma | 1 | 2005 | 190 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2005 | 167 | 0.060 |
Why?
| | Leukemia | 1 | 2005 | 229 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2043 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2006 | 716 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2530 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1204 | 0.040 |
Why?
| | Glucose | 1 | 2006 | 976 | 0.040 |
Why?
| | Adult | 3 | 2019 | 35423 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2019 | 115 | 0.040 |
Why?
| | Azacitidine | 1 | 2019 | 138 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 750 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 214 | 0.040 |
Why?
| | Female | 4 | 2019 | 68274 | 0.040 |
Why?
| | Genetic Testing | 1 | 2019 | 425 | 0.030 |
Why?
| | Sulfonamides | 1 | 2019 | 494 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7063 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 72 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2013 | 50 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2012 | 34 | 0.020 |
Why?
| | Bortezomib | 1 | 2012 | 44 | 0.020 |
Why?
| | Risk Factors | 1 | 2006 | 9804 | 0.020 |
Why?
| | Vincristine | 1 | 2011 | 109 | 0.020 |
Why?
| | Amyloid | 1 | 2012 | 84 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 162 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4927 | 0.020 |
Why?
| | Doxorubicin | 1 | 2011 | 319 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2011 | 657 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 327 | 0.020 |
Why?
| | Male | 4 | 2019 | 63248 | 0.020 |
Why?
| | Kidney | 1 | 2012 | 1330 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 404 | 0.010 |
Why?
| | Antigens, CD | 1 | 2005 | 480 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2005 | 1094 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5400 | 0.010 |
Why?
| | Time Factors | 1 | 2012 | 6579 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2012 | 14562 | 0.010 |
Why?
| | Adolescent | 1 | 2005 | 20241 | 0.000 |
Why?
| | Child | 1 | 2005 | 20860 | 0.000 |
Why?
|
|
Schuster's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|